Verapamil, a calcium channel blocker, was tested alone and in combination with oxybutynin chloride for its clinical effectiveness in the treatment of detrusor hy perreflexia in a spinal cord injured population. Fourteen patients with detrusor hyperreflexia were included. All patients were treated with oxybutynin chloride alone and with the combination of oxybutynin chloride and verapamil. Six of the patients were also studied on no medication and verapamil alone. Cystometric and clinical comparisons were made with each change in drug dosage. Verapamil 240SL, when used alone, produced a delay in the first detrusor contraction as compared to no medication in 5 of the 6 patients but clinical improvement was insignificant. Clinical improvement with tolerable side effects was noted in 13 of the 14 patients treated with the combination of oxybutynin chloride and verapamil over oxybutynin alone. Our early experience with verapamil sug gests that it may be a valuable adjunct in the treatment of detrusor hyperre flexia.
occur interfering with the patient's ability to drive, read or work. For these reasons, we have been interested in evaluating other agents to either replace or augment the actions of oxybutynin.
Terodiline, which is not yet available in the United States, has been reported by Scandinavian investigators to control motor urge incontinence in non paralysed women by combining calcium antagonist, anticholinergic, spos moly tic, and local anesthetic properties. (Andersson, 1984; Henry, 1980; Klarskov et ai., 1986; Lukkarinen et ai., 1987 ) . The calcium channel blocking agent verapamil, has been reported to have the ability to prevent detrusor con tractions both in experimental animals in vitro and in vivo by interfering with the passage of calcium ions into smooth muscle cells (Andersson et ai., 1986; Khanna et ai., 198 3; Maggi et ai., 1982; Maggi et ai., 1984 ) . The primary use of this drug has been in the treatment of cardiac arrhythmias in humans. We were interested in testing the effect of verapamil alone and in combination with ox ybutynin chloride, an anticholinergic, sposmolytic in the treatment of detrusor hyperreflexia. Our initial experience with verapamil for the treatment of de trusor hyperreflexia is reported herein.
Patients and tnethods

Fourteen pati�nts followed up by the spinal cord injury units at Cleveland
Metropolitan General Highland View Hospital and the Cleveland Veterans Ad ministration Medical Centre with detrusor hyperreflexia who complained of intolerable side-effects from their dosage of oxybutynin choloride were entered in the study. There were 10 men and 4 women. Patients age ranged from 19 to 55 years with a mean of 34·2 years. Ten of the patients were on intermittent catheterisation and 4 had indwelling catheters. Eleven of the patients had urine leakage between intermittent catheterisations or leakage about the catheter that could not be managed with oxybutynin in dosages tolerable to the patient. Two additional patients were dry but complained of a severely dry mouth or blurred vision from the oxybutynin and were wet when the oxybutynin dosage was lowered. A final patient with detrusor-sphincter dyssynergia who had refused sphincterotomy had autonomic dysreflexia improved but not eliminated with oxybutynin and intermittent catheterisation. Twelve of the patients had spinal cord injury and 2 had neurological disease, one from spinocerebellar degenera tion and the other from multiple sclerosis. There were 5 cervical injuries (3 complete and 2 incomplete) and 7 thoracic injuries of which 6 were complete.
The mechanism of injury consisted of 5 motor vehicle accidents, 4 falls, 1 diving accident, and 2 transverse myelitis. Patients were entered in the study from 5 months to 27 years (mean of7·6 years) after spinal cord injury or diagnos is of the neurological disease. Informed consent was obtained from each patient.
Urine cultures were obtained and the urine was sterilised with appropriate antibiotics based upon sensitivity studies prior to starting a patient on the study.
Baseline water cystometrics were obtained on a DI SA Dantec 21 00 urovideo urodynamics unit and true bladder pressures were determined after subtracting rectal pressures. Urine cultures, liver function tests, and EKGs were obtained as baseline studies and repeated along with cystometrics and 3 to 7 days after each change in drug dosage. At least two different cystometrics were obtained on each drug dosage.
All patients were placed initially on oxybutynin. Eleven were on 5 mg q 6 hours, 2 were on 5 mg q 8 hours, and one was on 10 mg q 6 hours with imiprimine 50 mg hs. Six patients were taken off all medications for 3 to 7 days and baseline CMGs were obtained. These were then compared with those ob tained while treating the patient with verapamil 240 SL q am alone. Because of severe detrusor hyperreflexia, oxybutynin was not discontinued in the other 8 patients. Oxybutynin dosages were titrated from 2·5 mg q 8 hours to 5 mg q 6 hours until the patient complained that the side-effects were unpleasant.
Verapamil 240 SL was then added in the morning and if the patient was not dry with this combination an additional verapamil 120 SL was added at bed time. During the titration period, patients were kept on each drug dosage for a minimum of 3 to 7 days. Once the final drug dosage was determined, patients were followed on a monthly basis with liver functions repeated every 3 months. The average follow-up was 6 months.
Results
The effect that verapamil had on the first detrusor contraction is shown in the Table 1 ) Note the improvement in bladder capacity and decrease in intravesical pressure with verapamil over no medications, oxybutynin over verapamil alone, and oxybutynin and verapamil over oxybutynin alone.
oxybutynin dosages as they were on prior to the study but 8 of the 9 became clinically drier without increasing the oxybutynin dosage. It was pos sible to lower the dosage of oxybutynin in the remaining 5 patients with the addition of verapamil and these patients noted that they were clinically more dry than they had been on the higher dosages of oxybutynin alone. Table. The volume at which the first detrusor contraction occurred was increased in 12 of the patients on the com bination of oxybutynin with verapamil. Figure 1 reveals the cystometric find ings with various medications used in patient ;It 2 (described in the Table) . Pharmacological treatment in the US has for many years been the an ticholinergic drug oxybutynin chloride. While this medication is clinically ef fective, many patients become non-compliant in taking the drug because of the undesirable side-effects.
Calcium entry from an extracellular medium appears to play an important role in the activation of urinary bladder smooth muscle (Forman et ai., 1978) .
Drugs that block the influx of calcium should therefore be expected to have some inhibitory effect on bladder smooth muscle contraction. The combination of an anticholinergic with a calcium blocking agent offers the potential phar macotherapy advantage of increasing the therapeutic effectiveness while decreas ing the side-effects encountered with adequate dosages of anticholinergics (An dersson and Ulmsten, 1980 , Andersson, 1984 ) . Terodiline, a drug produced by the Kabi-Company (Sweden), an agent which combines anticholinergic, cal cium channel blocking, sposmolytic and local anesthetic properties has been reported to be more effective than placebo in the treatment of urge incontinence in non-paralysed women (Klarskov et ai., 1986 ; Lukkarinen et ai., 1987 ) . As this agent is not available in the United States, verapamil, a calcium channel blocker, that had been reported to block detrusor smooth muscle in vivo and in vitro (Henry, 1980 ; Khanna et ai., 1983 ) was chosen to be tested alone and in a combination with oxybutynin chloride.
From our initial experience, it appears that verapamil does delay the first detrusor contraction; however, when used alone, the effect was insufficient to be of any significant clinical value. The combination of verapamil and oxy butynin produced clinical improvement over oxybutynin alone in 13 of the 14 patients. The patient that showed no benefit had a small fibrotic bladder and was perhaps a poor candidate for this study and may require bladder augmentation. Side-effects of therapeutic dosages of the combination of verapamil with oxybutynin were better tolerated than clinically effective dosages of oxybutynin alone and consisted only of transient constipation. Dryness of mouth was improved.
Verapamil also appeared to blunt the hypertensive response elicited by cysto metrics in the 3 patients that had developed autonomic dysreflexia by this stimulus. This added effect of verapamil may make its utilisation in this patient population more desirable.
Conclusion
While this is an initial study on a limited number of patients, it would appear that verapamil is of benefit when used in combination with oxybutynin in the treatment of detrusor hyperreflexia. Side-effects with this combination were more tolerable than with oxybutynin alone. An added benefit appeared to be a blunting of autonomic dysreflexia once verapamil was begun. Further studies combining calcium channel blockers and anticholinergics appear warranted in the treatment of detrusor hyperreflexia. The combination may minimise side effects of the medications and improve patient compliance.
